Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
32
PACB Quote, Financials, Valuation and Earnings
Last price:
$1.85
Seasonality move
:
-22.94%
Day range:
$1.76 - $1.92
52-week range:
$0.85 - $2.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.59x
P/B ratio:
15.39x
Volume:
9.5M
Avg. volume:
8.2M
1-year change:
35.29%
Market cap:
$555.5M
Revenue:
$154M
EPS (TTM):
-$2.18
Analysts' Opinion
-
Consensus RatingPacific Biosciences of California, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.42, Pacific Biosciences of California, Inc. has an estimated upside of 31.34% from its current price of $1.84.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $1.84.
Fair Value
-
According to the consensus of 9 analysts, Pacific Biosciences of California, Inc. has 31.34% upside to fair value with a price target of $2.42 per share.
PACB vs. S&P 500
-
Over the past 5 trading days, Pacific Biosciences of California, Inc. has overperformed the S&P 500 by 8.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pacific Biosciences of California, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pacific Biosciences of California, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Pacific Biosciences of California, Inc. reported revenues of $38.4M.
Earnings Growth
-
Pacific Biosciences of California, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Pacific Biosciences of California, Inc. reported earnings per share of -$0.13.
Enterprise value:
956.6M
EV / Invested capital:
--
Price / LTM sales:
3.59x
EV / EBIT:
--
EV / Revenue:
6.19x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-7.29x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$324.7M
Return On Assets:
-48.31%
Net Income Margin (TTM):
-325.02%
Return On Equity:
-218.65%
Return On Invested Capital:
-51.88%
Operating Margin:
-100.96%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $169.5M | $173.1M | $154.6M | $40M | $38.4M | |
| Gross Profit | $46.9M | $9.6M | -$324.7M | $3M | $15.1M | |
| Operating Income | -$306.5M | -$288.6M | -$552M | -$56.2M | -$38.8M | |
| EBITDA | -$287.1M | -$228.4M | -$159.3M | -$40.1M | -$34.4M | |
| Diluted EPS | -$1.28 | -$1.46 | -$2.18 | -$0.22 | -$0.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $913.9M | $882.3M | $584.2M | $394.2M | |
| Total Assets | $2B | $1.8B | $1.9B | $1.5B | $803.2M | |
| Current Liabilities | $55.6M | $81.6M | $184M | $60M | $63.2M | |
| Total Liabilities | $1.2B | $1.2B | $1.1B | $996.9M | $767.1M | |
| Total Equity | $840.8M | $626.6M | $763.7M | $453.1M | $36.1M | |
| Total Debt | $953M | $939.7M | $926.1M | $910.1M | $699.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$269.5M | -$233M | -$122.8M | -$45.5M | -$18.7M | |
| Cash From Investing | $151.6M | -$809K | $147.7M | $23.1M | $18.9M | |
| Cash From Financing | $198.6M | -$74.3M | -$46.8M | $812K | $1.5M | |
| Free Cash Flow | -$281.4M | -$239.6M | -$131.3M | -$44.7M | -$18.6M | |
PACB
Sector
Market Cap
$555.5M
$23.4M
Price % of 52-Week High
67.4%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
10.75%
-1.64%
1-Year Price Total Return
35.29%
-21.81%
Beta (5-Year)
2.267
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.86
200-day SMA
Buy
Level
$1.60
Bollinger Bands (100)
Sell
Level
1.57 - 2.29
Chaikin Money Flow
Sell
Level
-8.1M
20-day SMA
Sell
Level
$2.18
Relative Strength Index (RSI14)
Sell
Level
40.02
ADX Line
Sell
Level
50.69
Williams %R
Buy
Level
-82.6068
50-day SMA
Sell
Level
$2.12
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Sell
Level
-38M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.122)
Sell
CA Score
(Annual)
Level (-1.6727)
Buy
Beneish M-Score
(Annual)
Level (-3.5629)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.788)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
Stock Forecast FAQ
In the current month, PACB has received 4 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PACB average analyst price target in the past 3 months is $2.42.
-
Where Will Pacific Biosciences of California, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pacific Biosciences of California, Inc. share price will rise to $2.42 per share over the next 12 months.
-
What Do Analysts Say About Pacific Biosciences of California, Inc.?
Analysts are divided on their view about Pacific Biosciences of California, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pacific Biosciences of California, Inc. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Pacific Biosciences of California, Inc.'s Price Target?
The price target for Pacific Biosciences of California, Inc. over the next 1-year time period is forecast to be $2.42 according to 9 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is PACB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pacific Biosciences of California, Inc. is a Hold. 5 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of PACB?
You can purchase shares of Pacific Biosciences of California, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pacific Biosciences of California, Inc. shares.
-
What Is The Pacific Biosciences of California, Inc. Share Price Today?
Pacific Biosciences of California, Inc. was last trading at $1.85 per share. This represents the most recent stock quote for Pacific Biosciences of California, Inc.. Yesterday, Pacific Biosciences of California, Inc. closed at $1.84 per share.
-
How To Buy Pacific Biosciences of California, Inc. Stock Online?
In order to purchase Pacific Biosciences of California, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PACB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PACB
Sector
P/E ratio
--
23.34x
PEG ratio
-0.02x
-0.01x
P/B ratio
15.39x
1.72x
Price / LTM sales
3.59x
1.51x
Growth Metrics
PACB
Sector
Revenue growth
-3.82%
3.21%
Earnings growth
43.24%
10.12%
Revenue (5-year growth)
11.12%
6.27%
Earnings forecast
-$0.13
-$0.19
Profitability
PACB
Sector
Profitability FY 2024
$23.7M
$2.7M
Return on invested capital
-51.88%
-33.62%
Return on assets
-48.31%
-29.68%
Return on equity
-218.65%
-38.89%
Earnings Date
Last Earnings Date
Feb
12
Next Earnings Date
Feb
13
Estimated Next Earnings Date
May
15
Balance Sheet
PACB
Sector
Total cash
$299M
$25M
Short term investments
$334.6M
$23.9M
Total assets
$1.3B
$72.8M
Long term debt
$699.5M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is down 39.93% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 36.39% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 35.78% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
